ArticleBiological procedures online2026
Identification and validation of serum SLIT1 as a biomarker for predicting anti-PD-1/PD-L1 resistance in non-small cell lung cancer.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundNon-small cell lung cancer (NSCLC), the predominant subtype of lung cancer, contributes greatly to cancer-related mortality worldwide. Although inhibitors of programmed cell death protein 1 (PD-1) and its ligand PD-L1 have markedly improved patient outcomes, treatment resistance remains a substantial clinical challenge, underscoring the need for more effective predictive biomarkers. This study aimed to identify novel biomarkers for predicting treatment efficacy and clinical prognosis by systematically analyzing serum protein profiles of patients with divergent immunotherapy responses using four-dimensional data-independent acquisition (4D-DIA) proteomics integrated with the DB4000 platform.
resultsA total of 49 differentially expressed proteins were identified between treatment-resistant and treatment-sensitive patients, with Slit Guidance Ligand 1 (SLIT1) exhibiting the most pronounced downregulation (log₂[fold-change] ≈ - 2.29, P = 0.0419). In an independent validation cohort, enzyme-linked immunosorbent assay indicated that SLIT1 expression was significantly higher in resistant patients than in sensitive patients (P < 0.0001). Furthermore, elevated SLIT1 expression was independently associated with shorter progression-free survival. A prognostic model integrating SLIT1 with other clinical variables demonstrated excellent discriminative performance (area under the curve = 0.964, 95% confidence interval: 0.929-0.998). Single-cell transcriptomic analysis further revealed a significant enrichment of SLIT1 expression within myeloid-lineage cells, particularly in M2-polarized macrophages (P = 0.0396), suggesting its involvement in modulating an immunosuppressive tumor microenvironment that may underlie treatment resistance.
conclusionsBy employing an integrated multiomics framework, this study validated serum SLIT1 as a pivotal biomarker for predicting resistance to PD-1/PD-L1 inhibitors in patients with NSCLC and concurrently elucidated its correlation with an immunosuppressive tumor microenvironment. These findings not only offer a potential predictive tool for clinical application but also lay the groundwork for future mechanistic investigations and the development of optimized therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.